Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy. - Oligonucleotide Therapeutics Society

Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy.

AUTHOR

OTS

DATE

December 31, 2019

CATEGORIES

Alternative splicing,Hot Papers,Splice modulation

SHARE

Post Views: 331

Aupy P, Echevarría L, Relizani K, Zarrouki F, Haeberli A, Komisarski M, Tensorer T, Jouvion G, Svinartchouk F, Garcia L, Goyenvalle A.

Mol Ther Nucleic Acids. 2019 Nov 27;19:371-383.

Related articles

Subscribe to our Newsletter

OTS_Logo_retina

Oligonucleotide Therapeutics Society

c/o Event Innovations, Inc.
4377 Newport Avenue
San Diego, CA 92107, USA

(619) 795-9458
info@oligotherapeutics.org

Resources

Stay Connected

Search

Subscribe in a reader

© Copyright 2012 – 2022 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing

Username/Email Address:
Password:
Forgot Password? | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone:
Organization Name
Select Sectors
By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

Already have an account? Login